Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

← Go back

Full NameDr Steven Gray

Clinical Medicine

Trinity College Dublin

Webpage:www.tcd.ie

Email hidden; Javascript is required.

Research Fields

genetics, genomics and molecular biology
cell and developmental biology/regenerative medicine
cancer/oncology
clinical trials
Other

Other Research Fields:

Epigenetics

Postgrad Medical Specialties

Medicine
Pathology

Medical Subspecialties

Endocrinology
Oncology
Respiratory Medicine

My Work

Research in my lab includes:
1. Epigenetic mechanisms underpinning drug resistance in cancer.
2. Targeting Epigenetic Readers, Writers and Erasers in cancer
3. Circulating Tumour Cells in cancer
4. non-coding RNA repertoires in Prostate Cancer, Mesothelioma and Thoracic malignancy.
5. nanoparticles
6. Cancer Stem Cells
7. Utilizing epigenetic targeting agents to enhance onco-immunology
Recent Publications
1. MacDonagh L, Gray SG, et al. (2018). “Reversing cisplatin resistance in non‐small cell lung cancer using BBI608, a cancer stemness inhibitor”. Cancer Lett. 2018 Apr 10. pii: S0304-3835(18)30269-6. doi: 10.1016/j.canlet.2018.04.008.
2. Mohamed BM, Boyle NT, Schinwald A, Murer B, Ward R, Mahfoud OK, Rakovich T, Crosbie-Staunton K, Gray SGet al. (2018). “Induction of protein citrullination and auto-antibodies production in mice exposed to nickel nanomaterials”. Scientific Reports;8(1):679.
3. MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, et al. (2017). “Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.” Oncotarget. 8(42):72544-72563.
4. Dockry É, O’Leary S, Gleeson LE, Lyons J, Keane J, Gray SG*, Doherty DG* “Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells” OncoImmunology In Press (* contributed equally to the direction of this study)